晚期前列腺癌伴DNA错配修复基因突变患者的临床特征与治疗结局
Mismatch repair (MMR) gene mutations are rare in prostate cancer, and their histological and clinical characteristics are largely unknown.…
要点
- MMR突变晚期前列腺癌虽侵袭性强,但对激素治疗反应持久。
- grade group 5或导管内癌组织学特征应提示评估MMR缺陷。
- PD-1抑制剂在部分MMR突变患者中可见PSA应答。
核心结论
- MMR基因突变的晚期前列腺癌临床病理特征侵袭性强,但对标准及新型激素治疗敏感,对PD-1抑制剂有 anecdotal 敏感性。
主要发现
- 中位年龄64岁,75%为grade group 5(Gleason评分9或10),23%有导管内组织学,46%初诊即转移,31%有内脏转移。
- 46%患者为MSH6突变,73%显示微卫星不稳定,中位肿瘤突变负荷18/Mb(范围3-165突变/Mb)。
- 初始雄激素剥夺治疗的中位无进展生存期(PFS)为67个月,阿比特龙/恩扎卢胺的中位PFS为26个月。
- 4例接受PD-1抑制剂的患者中2例在12周时PSA下降≥50%,这4例的中位PFS为9个月。
临床怎么用
- 对于grade group 5或导管内癌组织学特征的前列腺癌,应考虑评估MMR缺陷。
- MMR突变晚期前列腺癌患者可优先考虑标准或新型激素治疗。
- PD-1抑制剂可作为部分MMR突变患者的治疗选择,但需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mismatch repair (MMR) gene mutations are rare in prostate cancer, and their histological and clinical characteristics are largely unknown. We conducted a retrospective study to explore disease characteristics and treatment outcomes of men with metastatic prostate cancer harboring germline and/or somatic MMR mutations detected using clinical-grade genomic assays. Thirteen patients with a deleterious MMR gene mutation were identified. Median age was 64 yr, 75% had grade group 5 (Gleason sum 9 or 10), 23% had intraductal histology, 46% had metastatic disease at initial diagnosis, and 31% had visceral metastases. Most patients (46%) had MSH6 mutations, 73% demonstrated microsatellite instability, and median tumor mutational load was 18/Mb (range, 3-165 mutations/Mb). Surprisingly, responses to standard hormonal therapies were very durable (median progression-free survival [PFS] of 67 mo to initial androgen deprivation and median PFS of 26 mo to abiraterone/enzalutamide). Two of four men receiving PD-1 inhibitors achieved a ≥50% prostate-specific antigen response at 12 wk, with a median PFS duration in these four men of 9 mo. Despite aggressive clinical and pathological features, patients with MMR-mutated advanced prostate cancer appear to have particular sensitivity to hormonal therapies, as well as anecdotal responses to PD-1 inhibitors. Certain histological features (grade group 5, intraductal carcinoma) should prompt evaluation for MMR deficiency. These data are only hypothesis generating. PATIENT SUMMARY: Prostate cancers with mismatch repair gene mutations have aggressive clinical and pathological features; however, these are very sensitive to standard and novel hormonal therapies, and also demonstrate anecdotal sensitivity to PD-1 inhibitors such as pembrolizumab.
引用
- Antonarakis ES, Shaukat F, Isaacsson Velho P, et al. Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations. Eur Urol. 2018. PMID: 30337059. doi:10.1016/j.eururo.2018.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。